Piramal Pharma Solutions a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. announced that it completed more than 200 customer audits and received over 70 approvals from regulatory agencies...
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Bortezomib for Injection in the United States. The product contains the same active ingredient as VELCADE®, as approved by...
Nestlé Health Science, a global leader in the science of nutrition, and IdB Holding S.p.A. (IdB), a global leader in the production of high potent active pharmaceutical ingredients for the pharmaceutical and the health food industries, announced...
LIB Therapeutics Inc. (LIB), a privately-held, biopharmaceutical company with a recently approved novel, monthly, small-dose, third-generation PCSK9 inhibitor, LEROCHOL® (lerodalcibep-liga), announced results from two oral and two poster...
BD (Becton, Dickinson and Company) a leading global medical technology company, today announced that Peter Menziuso has been named executive vice president and president, BD Interventional, effective June 1. Menziuso brings more than 30 years of...
Merck known as MSD outside of the United States and Canada, and Eisai today announced the first presentation of results from the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG® (belzutifan). Merck’s first-in-class oral...
Astellas Pharma U.S., Inc. announced the publication of exploratory ad hoc analyses from the combined Phase 3 SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) studies in patients with HER2-negative, CLDN18.2-positive advanced gastric or...
Samsung Bioepis Co., Ltd. announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis1 (ranibizumab), in Europe. Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen...
UCB, a global biopharmaceutical company, announced three-year data from the BE HEARD trials for BIMZELX® (bimekizumab-bkzx) in moderate-to-severe hidradenitis suppurativa (HS). BIMZELX, the first and only medicine approved to selectively inhibit...
Samsung Epis Holdings Co., Ltd. announced its establishment as a new investment holding company, following the spin-off of Samsung Bioepis Co., Ltd. from Samsung Biologics (KRX: 207940.KS). Samsung Epis Holdings will be listed on Korea Exchange...
Merck known as MSD outside of the United States and Canada, announced positive topline results from the Phase 3 LITESPARK-022 trial in patients with clear cell renal cell carcinoma (RCC) following nephrectomy. In this study, KEYTRUDA®...
Alteogen Inc. announced today that the European Commission (EC) has granted marketing authorization for EYLUXVI® (code name: ALT-L9), an Eylea® biosimilar co-developed by its subsidiary, Alteogen Biologics. EYLUXVI® is Alteogen's second approved...
Acadia Pharmaceuticals Inc. announced that the journal Developmental Medicine and Child Neurology published interim results from the caregiver-reported observational online, open-label, ongoing LOTUS study evaluating effectiveness and tolerability...
Nuvation Bio Inc. a global oncology company focused on tackling some of the toughest challenges in cancer treatment, announced new and updated results from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating IBTROZI™ (taletrectinib) for...
SkinCeuticals, the #1 Medical Aesthetic Skincare Brand Worldwide*, announces the launch of A.G.E. Interrupter Ultra Serum, the latest science-backed product in its A.G.E. line. Sagging skin is a top concern driving patients to dermatologists, and...
Nuvation Bio Inc. a global oncology company focused on tackling some of the toughest challenges in cancer treatment, announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI™ (taletrectinib) for the treatment of adult...
Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab demonstrated a highly statistically significant and clinically...
Daicel Arbor Biosciences, a company that offers tools and services to accelerate genomics and synthetic biology research, in collaboration with Element Biosciences, a life sciences company democratizing access to advanced biological tools, is...
Hanmi Pharmaceutical's combination therapy for Obstructive Prostatic Growth (OPG) caused by Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED), Gugutams, is entering the Mexican market under the local brand name "Aditams." Hanmi...
Attendees at this year's American College of Foot and Ankle Surgeons Annual Meeting in Phoenix, Ariz. will be the first to see Medline UNITE's new Synthetic Ligament Augmentation implant. The intelligently designed solution provides the next...
